Inmune Bio Inc. 8-K Report: Key Insights on Major Events (Feb 10, 2025)

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:
- Entity Information:
- Name: Inmune Bio Inc.
- CIK Number: 0001711754
- SEC File Number: 001-38793
- EIN: 47-5205835
- Address: 225 NE Mizner Blvd. Suite 640, Boca Raton, FL 33432
- Phone Number: 858-964-3720
- Filing Type:
- Form Type: 8-K, which is used to report major events that shareholders should know about.
- Filing Date:
- Date of Report: February 10, 2025.
- Stock Information:
- Security Type: Common Stock
- Par Value: $0.001 per share
- Ticker Symbol: INMB
- Exchange: NASDAQ
- Context and Units:
- The report is structured with a context defined for the date of February 10, 2025, indicating that the information reported is as of this date.
- The report utilizes various units of measure, including USD for monetary values and shares for equity.
Insights:
- The report is part of a regulatory requirement for Inmune Bio Inc., indicating that there may have been significant events or changes that warranted immediate disclosure.
- The presence of the form type (8-K) suggests that investors and stakeholders should pay attention to the details contained within, as it may impact stock performance or corporate strategy.
- Given the company's listing on NASDAQ, it is important for investors to monitor this filing for any material changes that could affect share price.
Overall, this 8-K filing serves as an important communication tool between Inmune Bio Inc. and its shareholders, providing necessary transparency regarding corporate events and financial standing as of February 10, 2025.